AVR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Anteris Technologies (AVR) is not a strong buy for a beginner long-term investor at the moment. While the company has a promising product pipeline and positive analyst sentiment, the recent financial performance, lack of significant trading signals, and mixed options data suggest caution. The investor may consider monitoring the stock for further developments, especially as the company progresses toward FDA approval and commercialization of its TAVR platform.
The technical indicators show a mixed picture. The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 56.1, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating a potential upward trend. However, the stock's recent price decline (-5.25% in regular trading) and pre-market drop (-0.32%) suggest short-term weakness. Key support levels are at 5.167, with resistance at 6.283.
Analysts have consistently rated the stock as Overweight with price targets ranging from $15 to $17, indicating significant upside potential.
The company's DurAVR platform is seen as a disruptive technology in the $12.4B TAVR market, with potential to capture market share.
Recent financing has reduced capital risk and attracted strategic investment from Medtronic, a major player in the industry.
Recent financial performance shows a 42.18% YoY revenue decline, despite improvements in net income and EPS.
Lack of recent news or significant trading trends from hedge funds and insiders.
The options market reflects bearish sentiment, with high put-call ratios and elevated implied volatility.
In Q4 2025, revenue dropped by 42.18% YoY to $310,000, indicating challenges in revenue generation. However, net income improved by 50.72% YoY to -$29.2M, and EPS increased by 37.04% YoY to -0.74, showing some progress in cost management. Gross margin improved to 70.65%, up 15.35% YoY, reflecting operational efficiency gains.
Analysts are optimistic about Anteris Technologies, with Overweight ratings and price targets between $15 and $17. They highlight the company's potential to disrupt the TAVR market with its differentiated DurAVR platform and note reduced financing risks following a strategic investment from Medtronic.
